
Opinion|Videos|May 8, 2024
Clinical Evidence for Emerging PAH Therapies
Dr Oudiz discusses clinical data that support the efficacy and safety of emerging PAH therapies and ongoing research in the treatment space.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What clinical data support the efficacy and safety of these new treatments, and how do they compare to existing therapies?
- Are there any ongoing clinical trials evaluating promising investigational agents or combination therapies for pulmonary arterial hypertension (PAH)?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL
2
Global CKD Burden Nearly Doubles Since 1990, Reaching 788 Million Adults Worldwide
3
Ibrutinib-Based Frontline Regimens Narrow the Survival Gap in CLL
4
Missed Hepatitis B Treatment Opportunities in the US Increase Health Risks
5
















































